Xeomin Cosmetic® Licensed for Additional Indications In Canada
Xeomin Cosmetic® Licensed for Additional Indications In Canada Expanded indications build on 10 years of proven efficacy and safety1 BURLINGTON, ON, Nov. 7, 2019 /CNW/ – Merz Pharma Canada Ltd., an affiliate of the global Merz Pharma Group, has announced that Health Canada has provided marketing authorization for additional indications for Xeomin Cosmetic® (botulinum toxin … Continue reading Xeomin Cosmetic® Licensed for Additional Indications In Canada
Digital Health Week 2019: Join the Celebration!
Digital Health Week 2019: Join the Celebration! TORONTO, Nov. 7, 2019 /CNW/ – Canada Health Infoway (Infoway) is inviting Canadians to participate in Digital Health Week 2019 (Nov. 11-17) to celebrate how digital health is transforming health care in Canada. This is the sixth year for this nationally recognized awareness week, which is once again being held … Continue reading Digital Health Week 2019: Join the Celebration!
Join Us in November—Parkinson’s Conferences start this weekend in Ontario
Join Us in November—Parkinson’s Conferences start this weekend in Ontario TORONTO, Nov. 7, 2019 /CNW/ – Parkinson Canada, the definitive voice for the Parkinson community in Canada, is pleased to offer the following educational events, in Toronto, Hamilton and London, Ontario this month. These informative sessions are created for people with Parkinson’s, their caregivers and … Continue reading Join Us in November—Parkinson’s Conferences start this weekend in Ontario
Proposed Changes to OHIP include Fundamentally Flawed Policies
Proposed Changes to OHIP include Fundamentally Flawed Policies TORONTO, Nov. 7, 2019 /CNW/ – Ontario’s doctors have always supported a fair and transparent process regarding billing information. It is important for taxpayers to know where their hard-earned dollars are going. Some changes proposed by the government of Ontario to the OHIP billing process include initiatives … Continue reading Proposed Changes to OHIP include Fundamentally Flawed Policies
Janssen Announces Health Canada Approval of IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Janssen Announces Health Canada Approval of IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia Patients experienced a 77 per cent reduction in risk of disease progression or death compared to chlorambucil plus obinutuzumab IMBRUVICA® Product Monograph now includes additional monotherapy long-term follow-up data TORONTO, Nov. 8, 2019 /CNW/ – The Janssen … Continue reading Janssen Announces Health Canada Approval of IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
